LAUSR

Abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) have been an important therapy in the treatment of a large number of cutaneous pathologies for more than three decades. Concerns have been raised that NSAIDs may be associated with an increased risk of adverse effects when used in patients with acute viral respiratory infections. Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is of extreme importance Although accumulating evidence support the existence of a harmful effect of NSAIDs in some infectious settings, no clinical studies demonstrating that such risk applies in case of COVID-19. Pending further research, a pragmatic and cautionary approach would be to avoid regular NSAID use or as first line option in suspicion of COVID19 symptoms.